- Title: Subtitle
- P-77. Improved Overall Survival With Axicabtagene Ciloleucel (Axi-Cel) vs Standard of Care (SOC) in Second-Line (2L) Large B-Cell Lymphoma (LBCL) Among the Elderly : A Subgroup Analysis of ZUMA-7
- Creators
- Perales Miguel-AngelMarie Jose KerstenUmar FarooqAaron RapoportFrederick LockeLori LeslieArmin GhobadiDavid MiklosCaron JacobsonJavier MunozPatrick JohnstonSamantha JaglowskiIan FlinnLinqiu DuChristina ToJason Westin
- Resource Type
- Abstract
- Publication Details
- The Journal of Japanese Society for Lymphoreticular Tissue Research, Vol.64(suppl), pp.120-120
- Publisher
- The Japanese Society for Lymphoreticular Tissue Research
- ISSN
- 1342-9248
- Language
- Japanese
- Date published
- 05/30/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984696822202771
Abstract
P-77. Improved Overall Survival With Axicabtagene Ciloleucel (Axi-Cel) vs Standard of Care (SOC) in Second-Line (2L) Large B-Cell Lymphoma (LBCL) Among the Elderly : A Subgroup Analysis of ZUMA-7
The Journal of Japanese Society for Lymphoreticular Tissue Research, Vol.64(suppl), pp.120-120
05/30/2024
Details
Metrics
4 Record Views